TABLE 2.
Clinical features and course of hVISA versus VSSA infection
| Characteristica | Value for the cohort |
P value | |
|---|---|---|---|
| hVISA (n = 29) | VSSA (n = 58) | ||
| Type of pneumonia (no. of patients [%]) | |||
| Community acquired | 6 (20.7) | 12 (20.7) | 1.000 |
| Health care associated | 12 (41.4) | 24 (41.4) | 1.000 |
| Hospital acquired | 5 (17.2) | 8 (13.7) | 0.753 |
| Ventilator associated | 6 (20.7) | 14 (24.1) | 0.792 |
| Antibiotic therapy (no. of patients [%]) | |||
| Vancomycin | 15 (51.7) | 38 (65.5) | 0.214 |
| Linezolid | 8 (29.6) | 12 (20.7) | 0.416 |
| Ceftaroline | 3 (10.3) | 3 (5.2) | 0.395 |
| TMP/SMX | 1 (3.4) | 2 (3.4) | 1.000 |
| Median time (h) to change in therapy (IQR) | 66.6 (32.3–109.2) | 72.8 (38.7–160.4) | 0.263 |
| Median (IQR) LOS (days)b | 17.5 (11.0–30.5) | 17.5 (11.0–35.8) | 0.554 |
| Median (IQR) LOSPNA (days)b | 13 (7–24) | 11 (6–18) | 0.797 |
| ID consult (no. of patients [%]) | 16 (55.2) | 34 (58.6) | 0.717 |
| Concurrent bacteremia (no. of patients [%]) | 27 (93.1) | 52 (89.7) | 0.742 |
| Median (IQR) duration of bacteremia (days) | 2 (1–5) | 2 (1–5) | 0.901 |
| Presence of concurrent sites of infection (no. of patients [%]) | |||
| Skin/soft tissue | 7 (24.1) | 8 (13.8) | 0.229 |
| Deep abscess | 1 (3.4) | 0 (0.0) | 0.155 |
| Bone/joint | 2 (6.9) | 1 (1.7) | 0.213 |
| Infective endocarditis | 2 (6.9) | 2 (3.4) | 0.469 |
| Unknown | 2 (6.9) | 10 (17.2) | 0.187 |
| ICU admission by type (no. of patients [%]) | 23 (79.3) | 40 (70.7) | 0.390 |
| Burn/trauma | 6 (26.1) | 5 (12.5) | 0.187 |
| Medical | 15 (65.2) | 31 (77.5) | 0.379 |
| Surgical | 2 (8.7) | 5 (12.5) | 1.000 |
| Median (IQR) ICU LOS (days)b | 12 (5.5–22.5) | 13 (5.0–25.0) | 0.725 |
| Mechanical ventilation (any) (no. of patients [%]) | 18 (62.1) | 37 (63.8) | 0.875 |
| Presence of S. aureus isolate type (no. of patients [%]) | |||
| PVL positive | 6 (20.7) | 17 (29.3) | 0.390 |
| USA300 | 6 (20.7) | 16 (27.6) | 0.485 |
| SCCmec type II | 12 (41.4) | 25 (43.1) | 0.878 |
| agr group II | 16 (55.2) | 25 (43.1) | 0.288 |
| agr dysfunction | 12 (41.4) | 19 (32.8) | 0.429 |
| Presence of other respiratory pathogens (no. of patients [%]) | |||
| Acinetobacter spp. | 5 (17.2) | 6 (10.3) | 0.642 |
| Pseudomonas spp. | 5 (17.2) | 5 (8.6) | 0.362 |
| Klebsiella spp. | 1 (3.4) | 7 (12.1) | 0.190 |
| Streptococcal spp. | 2 (6.9) | 4 (6.9) | 1.000 |
a
IQR, interquartile range; LOS, length of stay; LOSPNA, length of stay postdiagnosis of pneumonia; ICU, intensive care unit; PVL, Panton-Valentine leukocidin; TMP/SMX, trimethoprim-sulfamethoxazole.
b
Censored for inpatient mortality.